Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants.

Drug metabolism and pharmacokinetics - 1 Oct 2018

Siu Y Amy, Hao Ming-Hong, Dixit Vaishali, Lai W George

Abstract excerpt

Celecoxib was characterized as a substrate of human cytochrome P450 (CYP) 2D6 in vitro. In recombinant CYP2D6, celecoxib hydroxylation showed atypical substrate inhibition kinetics with apparent Km, Ki, and Vmax of 67.2 μM, 12.6 μM, and 1.33 μM/min, respectively. In human liver microsomes (HLMs), a concentration-dependent inhibition of celecoxib hydroxylation by quinidine was observed after CYP2C9 and CYP3A4 were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C9
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Enzyme Inhibitors

Share to Molecular Structure

Share to Quinidine

Share to Structure-Activity Relationship

Share to Substrate Specificity

Source

Identifiers

PMID: 30219715
DOI: 10.1016/j.dmpk.2018.06.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants.PMID 30219715Read ↗

Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.Semantic proximity Read ↗

Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6.Semantic proximity Read ↗

Profile of the inhibitory effects of gefitinib on CYP2D6 variants in vitro.Semantic proximity Read ↗

Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.Semantic proximity Read ↗

Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.Semantic proximity Read ↗

Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.Semantic proximity Read ↗

Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.Semantic proximity Read ↗

In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism.Semantic proximity Read ↗

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.Semantic proximity Read ↗

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.Semantic proximity Read ↗

Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.